EGFR and neoplasm: CL4 displays a therapeutic effect against EGFR activation; however, EGFR inhibitors have failed to prove success as monotherapies for glioblastoma, as such, CL4 should be used as a shuttle for therapeutic or diagnostic agents to these tumours in order to have clinical success [107].